Stay up to date on our announcements, media coverage, and resources.

Press releases and statements

Our latest company updates, product launches, leadership announcements, and public statements.

Recent highlights

Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) in Chronic Spontaneous Urticaria at ACAAI 2026

Read more

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

Read more

Celltrion in the News

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

– STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] – STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. – Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider […]
Read more

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

– Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg – The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in December 2024 – […]
Read more

Celltrion USA Announces Appointment of Dr. Juby Jacob-Nara, M.D as Senior Vice President and Chief Medical Officer

·      Dr. Juby Jacob-Nara brings a wealth of medical and clinical development knowledge and extensive expertise across multiple therapeutic areas and will lead medical strategy at Celltrion USA JERSEY CITY, N.J., June 2, 2025 – Celltrion USA today announced the appointment of Dr. Juby Jacob-Nara, M.D. as Senior Vice President and Chief Medical Officer. […]
Read more

Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths

– YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] – Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeability (IC) designation applies to prefilled syringe (40mg) and autoinjectors (40mg and 80mg) INCHEON, South Korea, May 23, 2025 /– Celltrion, Inc. today announced that the U.S. Food and Drug Administration […]
Read more

Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)

– Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) – Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn’s disease and ulcerative colitis and underscore Celltrion’s commitment to advancing scientific understanding in the field of IBD   INCHEON, South Korea, April 28, 2025 — Celltrion, Inc. today announced […]
Read more

U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab)

· YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1]  · Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with moderate-to-severe plaque psoriasis  INCHEON, South Korea, April 14, 2025 /– Celltrion, Inc. today announced that the U.S. Food and […]
Read more

Media asset library

Assets and resources for journalists, partners, and stakeholders.

Access assets